Hutchison China MediTech Ltd ("Chi-Med")

Hutchison China MediTech Ltd ("Chi-Med"): Focused on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. Chi-Med has a portfolio of 8 drugs in clinical development from own discovery engine in its Innovation platform and a cash generating Commercial platform with 2,500+ sales reps. Launched fruquintinib, partnered with Eil Lilly, in late stage colorectal cancer in China in November 2018. Global collaboration with AstraZeneca in two registration enabling studies with savolitinib in Tagrisso refractory lung cancer that is MET+ and EGFRm+ (global) and MET Exon 14 deletion NSCLC (China). Potential to start two registration programs globally in 2020.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

Asia, US - Middle Atlantic

Clinical Stage

Marketed, Phase III, Phase l or ll

Disease Space

Anti-inflammatory, Autoimmune, Immunotherapy, Oncology

Finance

Profitable, Revenues

Industry

Biotechnology

Listing

Public, USA

Market Cap

1B +

Website:

http://www.chi-med.com/

Address:

230 Park Ave
10th Fl
New York, NY 10169
United States

Presentation:

Please reach out to Solebury Trout to request a presentation

More info:

Send Message to Request Information

My account:

Company Participants at Solebury Trout Management Access SF 2020

Christian Hogg, CEO
Mark Lee, SVP Corporate Finance and Development
May Wang, SVP BD & Strategic Alliances
Weiguo Su, PhD, EVP & CSO

Top 10 Holders of Hutchison China Meditech Ltd Sponsored ADR

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
Capital International, Inc.	3.49	4,805,189	164.00	13F	9/30/20
Capital Research & Management Co. (International Investors)	3.27	4,507,442	153.84	13F	9/30/20
M&G Investment Management Ltd.	2.47	3,400,816	116.07	13F	9/30/20
Sands Capital Management LLC	2.37	3,272,034	111.67	13F	9/30/20
Wellington Management Co. LLP	2.09	2,880,942	98.33	13F	9/30/20
Zeal Asset Management Ltd.	1.95	2,692,611	91.90	13F	9/30/20
Capital Research & Management Co. (World Investors)	1.65	2,271,707	77.53	Funds	12/31/20
Schroder Investment Management (Singapore) Ltd.	1.37	1,891,819	64.57	13F	9/30/20
Schroder Investment Management (Hong Kong) Ltd.	1.24	1,713,179	58.47	13F	9/30/20
BlackRock Fund Advisors	1.23	1,693,781	57.81	13F	9/30/20

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.